Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2350
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia ; volume:9 ; number:1 ; day:17 ; month:7 ; year:2008 ; pages:1-6 ; date:12.2008
BMC medical genetics ; 9, Heft 1 (17.7.2008), 1-6, 12.2008
- Creator
-
Kim, Shin-Young
- Contributor
-
Lim, Ji-Hyae
Yang, Jae-Hyug
Kim, Moon-Young
Han, Jung-Yeol
Ahn, Hyun-Kyong
Choi, Jun-Seek
Park, So-Yeon
Kim, Mi-jin
Ryu, Hyun-Mee
SpringerLink (Online service)
- DOI
-
10.1186/1471-2350-9-68
- URN
-
urn:nbn:de:1111-2016021834480
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Shin-Young
- Lim, Ji-Hyae
- Yang, Jae-Hyug
- Kim, Moon-Young
- Han, Jung-Yeol
- Ahn, Hyun-Kyong
- Choi, Jun-Seek
- Park, So-Yeon
- Kim, Mi-jin
- Ryu, Hyun-Mee
- SpringerLink (Online service)
Other Objects (12)
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
The angiogenic factors placental growth factor (PIGF) and soluble FMS-like tyrosine kinase 1 (sFlt-1) can be used for predicting preeclampsia and intrauterine growth restriction as well as classifying preeclampsia according to severity : = Die Angiogenesefaktoren Placental growth factor (PIGF) und soluble FMS-like tyrosine Kinase 1 (sFlt-1) könnten sowohl zur Prädiktion der Präeklampsie und der intrauterinen Wachstumsrestriktion, als auch für die Klassifikation des Schweregrades verwendet werden
Die Wertigkeit von placental growth factor (PlGF) und soluble fms-like tyrosine kinase-1 (sFlt-1) im Rahmen des Erst-Trimester-Screenings.
Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
FMS
FMS
FMS*
FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
The angiogenic factors placental growth factor (PIGF) and soluble FMS-like tyrosine kinase 1 (sFlt-1) can be used for predicting preeclampsia and intrauterine growth restriction as well as classifying preeclampsia according to severity : = Die Angiogenesefaktoren Placental growth factor (PIGF) und soluble FMS-like tyrosine Kinase 1 (sFlt-1) könnten sowohl zur Prädiktion der Präeklampsie und der intrauterinen Wachstumsrestriktion, als auch für die Klassifikation des Schweregrades verwendet werden
Die Wertigkeit von placental growth factor (PlGF) und soluble fms-like tyrosine kinase-1 (sFlt-1) im Rahmen des Erst-Trimester-Screenings.
Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
FMS
FMS
FMS*
FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
The angiogenic factors placental growth factor (PIGF) and soluble FMS-like tyrosine kinase 1 (sFlt-1) can be used for predicting preeclampsia and intrauterine growth restriction as well as classifying preeclampsia according to severity : = Die Angiogenesefaktoren Placental growth factor (PIGF) und soluble FMS-like tyrosine Kinase 1 (sFlt-1) könnten sowohl zur Prädiktion der Präeklampsie und der intrauterinen Wachstumsrestriktion, als auch für die Klassifikation des Schweregrades verwendet werden
Die Wertigkeit von placental growth factor (PlGF) und soluble fms-like tyrosine kinase-1 (sFlt-1) im Rahmen des Erst-Trimester-Screenings.
Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
FMS
FMS
FMS*